Clinical Trials
17 trialsNCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
NCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
NCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT06008405 2023-09-06
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05005299 2023-08-01
VICTORY
Melbourne Health
Phase 1 Unknown
NCT05970822 2023-08-01
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05426798 2022-06-22
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04429191 2021-06-11
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Jasper Therapeutics, Inc.
Phase 1 Unknown
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT03836690 2019-10-25
ToTem
University College, London
Phase 1 Unknown
NCT03235973 2018-06-28
CEREAL
Institut Paoli-Calmettes
Phase 1 Unknown
NCT02493829 2017-04-13
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
King's College London
Phase 1 Unknown
NCT02240537 2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1 Unknown
NCT01277484 2015-11-20
PODAC
Seoul St. Mary's Hospital
Phase 1 Unknown
NCT00004036 2013-12-19
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT01716364 2012-12-04
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Peter MacCallum Cancer Centre, Australia
Phase 1 Unknown